Oracle Health Sciences InForm Cloud Service 6.1 Expands RBM
Oracle Health Sciences announced the availability of Oracle Health Sciences InForm Cloud Service 6.1.
Oracle Health Sciences announced the availability of Oracle Health Sciences InForm Cloud Service 6.1. The latest release of the Oracle Health Sciences InForm data capture and management platform provides trial sponsors and contract research organizations (CROs) supports today’s complex trial protocols and environments with advanced data capture/query management and real-time, actionable visibility into data, as well as standards-based, integrated workflows. This latest release enables trial sponsors and CROs to further increase clinical trial speed, efficiency, and accuracy with new capabilities including:
· Expanded risk-based monitoring capacity that enables source verification at the individual and subject level.
· A single location for defining and managing study administrative data in Oracle Health Sciences Central Designer that streamlines trial workflow and simplifies the design, self-deployment, versioning, and maintenance of clinical studies.
· An advanced modeling environment that streamlines management and validation of in-place, protocol amendments.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
